Published online Apr 14, 2019. doi: 10.3748/wjg.v25.i14.1697
Peer-review started: January 14, 2019
First decision: February 21, 2019
Revised: March 6, 2019
Accepted: March 15, 2019
Article in press: March 16, 2019
Published online: April 14, 2019
There is increasing evidence that long non-coding RNAs (lncRNAs) play an important role in tumor progression. The lncRNA cancer susceptibility 19 (CASC19) is highly expressed in colorectal cancer (CRC) tissues, and may be associated with colon cancer progression. However, there has been no experimental evidence regarding the function of CASC19 in CRC.
Investigation of the functions of the lncRNA CASC19 may suggest potential molecular mechanisms of CRC carcinogenesis and progression, and may further offer the potential for future preventive and therapeutic innovations in the management of CRC.
We measured the lncRNA CASC19 expression in CRC tissues and pair-matched adjacent non-tumor tissues, and investigated biological functions and the possible molecular mechanisms of CASC19 in CRC.
We detected CASC19 expression in CRC tissues and pair-matched adjacent non-tumor tissues using quantitative real-time PCR. The biological behavior of CASC19 in vitro was then assessed by overexpression and knockdown of the expression of CASC19. In further molecular mechanism studies, we confirmed the possible molecular mechanisms by which CASC19 plays a role by overexpression and knockdown of the expression of downstream molecules of CASC19.
The lncRNA CASC19 was upregulated in CRC tissue, which was related to tumor stage and metastasis. The lncRNA CASC19 had a role of promoting proliferation, metastasizing ability, and epithelial-mesenchymal transition, and inhibiting apoptosis by regulating microRNA 140-5p/cell migration inducing hyaluronidase 1 (miR-140-5p/CEMIP) expression in CRC cells.
The lncRNA CASC 19 is overexpressed in CRC tissues and cell lines, which could promote CRC progression through regulating miR-140-5p/CEMIP.
Members of the CASC19/miR-140-5p/CEMIP axis may serve as useful targets for future preventive and therapeutic innovations in the management of CRC.